JNJ

237.86

+1.46%↑

UNH

273.01

-2.38%↓

TMO

560.86

-2.06%↓

ABT

108.19

+0.27%↑

ISRG

481.52

+3.05%↑

JNJ

237.86

+1.46%↑

UNH

273.01

-2.38%↓

TMO

560.86

-2.06%↓

ABT

108.19

+0.27%↑

ISRG

481.52

+3.05%↑

JNJ

237.86

+1.46%↑

UNH

273.01

-2.38%↓

TMO

560.86

-2.06%↓

ABT

108.19

+0.27%↑

ISRG

481.52

+3.05%↑

JNJ

237.86

+1.46%↑

UNH

273.01

-2.38%↓

TMO

560.86

-2.06%↓

ABT

108.19

+0.27%↑

ISRG

481.52

+3.05%↑

JNJ

237.86

+1.46%↑

UNH

273.01

-2.38%↓

TMO

560.86

-2.06%↓

ABT

108.19

+0.27%↑

ISRG

481.52

+3.05%↑

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

14.72 -3.85

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

14.53

Max

15.27

Galvenie mērījumi

By Trading Economics

Ienākumi

1.4M

676K

Pārdošana

961K

18M

P/E

Sektora vidējais

48.528

84.243

EPS

-0.034

Dividenžu ienesīgums

0.48

Peļņas marža

3.67

Darbinieki

212

EBITDA

-3M

2.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+23.38% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.28%

Nākamie ieņēmumi

2026. g. 2. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-30M

338M

Iepriekšējā atvēršanas cena

18.57

Iepriekšējā slēgšanas cena

14.72

Ziņu noskaņojums

By Acuity

28%

72%

58 / 352 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 5. febr. 00:00 UTC

Karstas akcijas

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

2026. g. 4. febr. 22:55 UTC

Peļņas

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

2026. g. 4. febr. 21:44 UTC

Peļņas

Arm Holdings 3Q Profit Falls Despite Revenue Growth

2026. g. 4. febr. 21:39 UTC

Peļņas

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

2026. g. 5. febr. 00:00 UTC

Peļņas

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

2026. g. 5. febr. 00:00 UTC

Peļņas

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

2026. g. 4. febr. 23:46 UTC

Tirgus saruna

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

2026. g. 4. febr. 23:45 UTC

Peļņas

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

2026. g. 4. febr. 23:32 UTC

Tirgus saruna

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

2026. g. 4. febr. 22:59 UTC

Iegādes, apvienošanās, pārņemšana

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

2026. g. 4. febr. 22:30 UTC

Peļņas

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

2026. g. 4. febr. 22:30 UTC

Peļņas

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

2026. g. 4. febr. 22:21 UTC

Peļņas

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

2026. g. 4. febr. 22:17 UTC

Tirgus saruna

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

2026. g. 4. febr. 22:15 UTC

Tirgus saruna

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

2026. g. 4. febr. 22:00 UTC

Tirgus saruna

ESG Roundup: Market Talk

2026. g. 4. febr. 21:53 UTC

Peļņas

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

2026. g. 4. febr. 21:51 UTC

Peļņas

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

2026. g. 4. febr. 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 4. febr. 21:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 4. febr. 21:50 UTC

Tirgus saruna
Peļņas

Auto & Transport Roundup: Market Talk

2026. g. 4. febr. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 4. febr. 21:45 UTC

Peļņas

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

2026. g. 4. febr. 21:44 UTC

Peļņas

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

2026. g. 4. febr. 21:43 UTC

Peļņas

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

2026. g. 4. febr. 21:41 UTC

Peļņas

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

2026. g. 4. febr. 21:36 UTC

Tirgus saruna

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

2026. g. 4. febr. 21:30 UTC

Peļņas

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

2026. g. 4. febr. 21:30 UTC

Peļņas

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

2026. g. 4. febr. 21:30 UTC

Peļņas

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

23.38% augšup

Prognoze 12 mēnešiem

Vidējais 19 USD  23.38%

Augstākais 19 USD

Zemākais 19 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

2

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

58 / 352 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat